Latest Trials Latest NewsFAQ

BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

Study to Develop a Prediction Model to Understand the Effect of Low-dose Aspirin on Cancer That Develops in the Colon and/or the Rectum, Diseases That Affects the Heart or Blood Vessels and Safety Outcomes in European Countries. The Study is Also Called PEACOS Model EU

Completed

Conditions: Cardiovascular Disease
Bleeding
Colorectal Cancer

Interventions: Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)

First Posted Date: 2019-04-05

Last Posted Date: 2021-02-01

Lead Sponsor: Bayer

Target Recruit Count: 2000000

Registration Number: NCT03904732

Locations: 🇬🇧
Mimicked Population, Mimicked Population, United Kingdom

A Trial to Study BAY1753011 in Patients With Congestive Heart Failure

Phase 2

Completed

Conditions: Heart Failure (HF)

Interventions: Other: Placebo BAY 1753011
Drug: BAY 1753011
Other: Placebo Furosemide
Drug: Furosemide

First Posted Date: 2019-04-03

Last Posted Date: 2022-04-18

Lead Sponsor: Bayer

Target Recruit Count: 482

Registration Number: NCT03901729

Locations: 🇦🇹
Universitätsklinikum St. Pölten, St. Pölten, Niederösterreich, Austria
🇦🇹
Medizinische Universität Graz, Graz, Steiermark, Austria
🇦🇹
Universitätsklinikum AKH Wien, Wien, Austria

and more 63 locations

PROMES: A Clinical Study in Which Researchers Want to Learn More About the Safety Profile of MESIGYNA (Norethisterone Enantate 50 mg and Estradiol Valerate 5 mg) Used as a Medication to Prevent Pregnancy for Adult Women in Reproductive Age in the Peruvian Population at the Outpatient Clinic.

Completed

Conditions: Contraceptive

Interventions: Drug: Norethisterone enantate/estradiol valerate (Mesigyna, BAY98-7040)

First Posted Date: 2019-04-03

Last Posted Date: 2022-12-21

Lead Sponsor: Bayer

Target Recruit Count: 296

Registration Number: NCT03901131

Locations: 🇵🇪
Many locations, Multiple Locations, Peru

Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).

Completed

Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC)

Interventions: Drug: Radium-223 (Xofigo, BAY88-8223)
Drug: Abiraterone
Drug: Enzalutamide

First Posted Date: 2019-04-01

Last Posted Date: 2021-12-29

Lead Sponsor: Bayer

Target Recruit Count: 346

Registration Number: NCT03896984

Locations: 🇺🇸
US Flatiron prostate cancer database, Whippany, New Jersey, United States

A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed

Phase 2

Completed

Conditions: Solid Cancer

Interventions: Drug: BAY73-4506 (Regorafenib, Stivarga)

First Posted Date: 2019-03-26

Last Posted Date: 2024-04-02

Lead Sponsor: Bayer

Target Recruit Count: 6

Registration Number: NCT03890731

Locations: 🇩🇪
Universitätsklinikum Köln, Köln, Nordrhein-Westfalen, Germany
🇩🇪
Eberhard-Karls-Universität Tübingen, Tübingen, Baden-Württemberg, Germany
🇮🇹
A.O.U. Careggi, Firenze, Toscana, Italy

and more 3 locations

A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF)

Active, not recruiting

Conditions: Non-valvular Atrial Fibrillation (NVAF)

Interventions: Drug: Rivaroxaban (Xarelto,Bay 59-7939)

First Posted Date: 2019-03-25

Last Posted Date: 2024-12-10

Lead Sponsor: Bayer

Target Recruit Count: 504

Registration Number: NCT03887780

Locations: 🇮🇳
Sunshine Hospital, Secunderabad, Delhi, India

Study to Test the Usability of a New Injector to Administer Contrast Media Into Humans for Diagnostic Purposes

Not Applicable

Completed

Conditions: Computed Tomography

Interventions: Device: Stellant MP injector
Device: Centargo injector (BPI 1000045)

First Posted Date: 2019-03-14

Last Posted Date: 2021-03-03

Lead Sponsor: Bayer

Target Recruit Count: 425

Registration Number: NCT03875469

Locations: 🇳🇱
Maastricht University Medical Center, Maastricht, Limburg, Netherlands
🇦🇺
Medscan, Merrylands, New South Wales, Australia

Study Performed at Various Medical Centers to Learn More About Survival and Expected Course of Pulmonary Arterial Hypertension, a Type of High Blood Pressure in the Lungs Related to the Narrowing of the Small Blood Vessels in the Lungs

Completed

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: PAH medication

First Posted Date: 2019-03-05

Last Posted Date: 2021-05-04

Lead Sponsor: Bayer

Target Recruit Count: 104

Registration Number: NCT03863990

Locations: 🇦🇷
Many facilities, Multiple Locations, Argentina

A Study to Gain Information How Well Dexpanthenol Dermal Spray Helps the Skin to Recover After a Peeling in the External Genital Area of Women

Phase 4

Completed

Conditions: Skin Recovery

Interventions: Drug: BAY207543 (Bepanthol, Bepantol® Derma Spray)
Other: Semisolid vaseline

First Posted Date: 2019-02-25

Last Posted Date: 2020-03-11

Lead Sponsor: Bayer

Target Recruit Count: 33

Registration Number: NCT03853512

Locations: 🇧🇷
Medcin Instituto da Pele, Sao Paulo, Brazil

A Study to Gain Information How Well Dexpanthenol Dermal Spray Helps the Skin to Recover After Laser Hair Removal in the Groin and Intimate Area

Phase 4

Completed

Conditions: Skin Recovery

Interventions: Drug: BAY207543 (Bepanthol, Bepantol® Derma Spray)
Other: Semisolid vaseline

First Posted Date: 2019-02-25

Last Posted Date: 2020-03-11

Lead Sponsor: Bayer

Target Recruit Count: 35

Registration Number: NCT03853525

Locations: 🇧🇷
Medcin Instituto da Pele, Sao Paulo, Brazil

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy